Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Haemonetics Corp HAE

Healthcare Medical Instruments & Supplies
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma... see more

Recent & Breaking News (NYSE:HAE)

Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

PR Newswire November 7, 2024

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024

PR Newswire October 3, 2024

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

GlobeNewswire September 24, 2024

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

PR Newswire August 15, 2024

Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

PR Newswire August 8, 2024

Sotera Health Appoints Christopher Simon to the Board of Directors

GlobeNewswire August 1, 2024

Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire

PR Newswire July 30, 2024

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024

PR Newswire July 8, 2024

Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

PR Newswire June 18, 2024

Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes

PR Newswire May 23, 2024

Haemonetics Announces Proposed Convertible Senior Notes Offering

PR Newswire May 21, 2024

Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website

PR Newswire May 9, 2024

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

PR Newswire April 10, 2024

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge

PR Newswire April 4, 2024

Haemonetics Corporation Completes Acquisition of Attune Medical

PR Newswire April 1, 2024

Haemonetics Announces Definitive Agreement to Acquire Attune Medical

PR Newswire March 5, 2024

Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

PR Newswire February 21, 2024

Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

PR Newswire February 21, 2024

Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

PR Newswire February 8, 2024

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024

PR Newswire January 11, 2024